Viruses know no borders, and pandemics spare no race. Only through solidarity and collaboration can we overcome the pandemic and safeguard our shared home. Since the outbreak began, Kintgen Biotech, as a leading enterprise in China’s vaccine industry, has actively joined the fight against the epidemic and has worked with… 2021 year 5 At the end of the month, we obtained approval for conditional market authorization from the national authorities. This process served as a mirror, showcasing our team’s determination and perseverance in effectively integrating corporate resources, and approximately… 200 Employee Yu Minhai has enthusiastically and proactively contributed to advancing the Kintor COVID‑19 vaccine project, demonstrating the spirit of resilience and determination that defines the Kintor Minhai team, as well as their unwavering dedication and the passion and culture that drive the team.

Through relentless efforts, a new record was set for equipment commissioning — Li Guanghui, New Engineering Project Department.

On the evening of March 13, Li Guanghui, Director of the Engineering Equipment Department, received instructions from company leadership to immediately travel to the COVID‑19 project site to oversee construction and equipment installation and commissioning for Building No. 3, ensuring that the national inspection would be completed by April 1 and production conditions would be met. Upon receiving these directives, Li Guanghui led his engineering support team straight to the Xili base. Faced with an extensive array of tasks—including cleanroom construction, pipeline installation, electrical distribution and fire‑protection systems, civil works, and fine interior finishing—and with the need to advance the original installation and commissioning schedule by more than a month, Li remained calm under pressure. He promptly revised the installation and commissioning plan, organized his team to work around the clock, and ensured no hour was wasted. Throughout the process, he closely monitored the installation and commissioning site, coordinating to resolve issues raised by suppliers. To prevent repeated visits from the national inspection team, he adopted a time‑management strategy: once one of the four negative‑pressure zone BMS systems was properly calibrated, VHP disinfection and sterilization were carried out that very night, with operational mode changes conducted in parallel. Suppliers, the project team, and QA worked in close collaboration, pulling five all‑night shifts to successfully validate the air‑conditioning system, pipeline BIBO, and sterile isolator VHP disinfection. From the 27th through the morning of the 31st—just three and a half days—the national inspection was smoothly completed, setting a new record for engineering commissioning in close coordination with other teams. This ensured the company was fully prepared to undergo the national biosafety certification from April 7 to 9, and on April 16, it received official approval for passing the national biosafety assessment and proceeded with the first batch of virus inoculation.

Striving for excellence, learning rapidly, and ensuring timely completion of emergency testing tasks — Quality Control Department, Zheng Xuexue

When she learned that Kangtai Construction had a COVID‑19 project, Zheng Xuexue was eager to contribute her expertise. Upon receiving the order to join the Kangtai project, she promptly handed over her ongoing responsibilities and threw herself into the effort. Soon after work began, she encountered a significant challenge: obtaining biosafety certification for Workshop B. Biosafety was a relatively new field for her team. Faced with this obstacle, she led her team in poring over extensive documentation, conducting on‑site training, and systematically organizing their findings—often without even time to eat. They worked late into the night, frequently not returning to their apartments until 2 a.m., and ultimately, thanks to the concerted efforts of the entire department, they successfully secured biosafety accreditation.

After the project went into production, the pressure on them intensified. Even a simple test for protein content became extraordinarily complex in the P3 laboratory. Technicians had to stand for seven to eight hours at the isolator, wearing respirators and positive-pressure hoods, completing their analyses; by the time they emerged, their backs ached and their bodies were exhausted. The deep imprints left by masks on their faces and their weary expressions were truly heartbreaking. With emergency use authorization granted, they dared not delay a single day in carrying out their testing duties, often working overtime until the early hours of the morning—and frequently pulling all‑night shifts. No matter how grueling or exhausting it was, they motivated themselves with the principle that “delaying production is tantamount to letting down the nation’s expectations,” never allowing themselves to slacken in the slightest.

For her, the happiest moment of each day is video‑calling her child, though she often misses it because of back-to-back meetings. One time stands out: on Children’s Day, the kindergarten teacher asked her to record a video with best wishes for her child, and when the little one saw it, he burst into tears. He keeps asking, “Mom, how much longer until you come home?” Zheng Xuexue always replies, her eyes welling up, “Once we’ve beaten the virus, Mom will be home!” Though she herself can’t say exactly how long it will take, she firmly believes that hard work is life’s most radiant brilliance—and that contributing to the research and production of COVID‑19 vaccines is a once‑in‑a‑lifetime opportunity that demands all her effort.

  897 Model, build the team, and strive for our dreams — Zhang Qian, International Cooperation Department

As the COVID‑19 project progressed, clinical and international collaborations related to the pandemic were also advancing in close coordination. After the May Day holiday, the International Cooperation Department relocated its entire team to the Kangtai site, and Manager Zhang Qian’s immediate reaction was that it was time to roll up our sleeves and get down to business. Taking the opportunity presented by the COVID‑19 vaccine initiative, the department seized this as an excellent chance to hone its skills and elevate both individual and collective capabilities. To work more effectively, she patiently persuaded her family and won their support and understanding, bringing her children and her household along as she headed straight into the front lines of the COVID‑19 program. The department’s staff generally worked long hours—8 a.m. to 9 p.m., seven days a week. With many South American partners operating across a 12‑hour time difference, holding meetings or coordinating with them at 8 a.m. or between 10 and 11 p.m. was routine. It was common to juggle five or six meetings from morning till night, followed by internal discussions and a mountain of team‑level tasks. Amidst the pressure, chaos, and rapid‑fire communication, she kept encouraging herself whenever things felt overwhelming—until, finally, the moment she received the scanned copy of the clinical trial approval from the partner, when she could truly savor the joy and pride of achieving yet another small milestone.

During this support effort for the Kangtai COVID‑19 project, the company’s relevant departments and all participating personnel acted with great initiative, upholding the values of fearlessly facing challenges and taking pride in selfless dedication, thereby making significant contributions to the concrete advancement of the project. They are a vivid embodiment and concentrated representation of Minhai employees’ commitment to this cause. We hope that all Minhai colleagues will remain steadfast in their aspiration to contribute to the nation’s fight against the pandemic, stay true to their original mission in their respective roles, and earnestly and resolutely uphold Kangtai Minhai’s distinguished corporate culture. Let us forge ahead with renewed vigor, strive with unwavering determination, and work together to make even greater contributions to the company’s development and to the health of our people.